AHK-Cu
L-Alanyl-L-Histidyl-L-Lysine Copper(II) Complex (Copper Tripeptide-3)
This peptide has not been evaluated by the FDA. It is sold as a research chemical and has no regulatory status for human use.
A copper-binding peptide with one laboratory study suggesting it may help stimulate hair follicle growth in human tissue samples. No human clinical trials have been conducted, so its effectiveness and safety in people are not yet established.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
AHK-Cu is preclinical or hypothesis-only.
This peptide has not been evaluated by the FDA. It is sold as a research chemical and has no regulatory status for human use.
Safety Summary
No formal adverse event data exists for AHK-Cu from clinical trials. The FDA FAERS and ClinicalTrials.gov files in this project contained no peptide-specific matches. Side effect information is derived from available literature. Copper peptides as a class have a long track record of topical safety in cosmetic use, but formal controlled safety trials specific to AHK-Cu have not been conducted.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Cited sources
Every claim on this page links to one of the 2 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.
- 1PMID 17703734PubMed
- 2PMID 34377956PubMed